A Custodio

Summary

Publications

  1. ncbi Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review
    Ana Belén Custodio Carretero
    Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 10:560-71. 2008
  2. ncbi Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer
    Ana Belén Custodio
    Medical Oncology Department, Hospital Universitario Clinico San Carlos, Center affiliate to the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto de Salud Carlos III ISCIII, Madrid, Spain
    J Thorac Oncol 4:891-910. 2009
  3. ncbi Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions
    Ana Custodio
    Department of Medical Oncology, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Cancer Treat Rev 35:676-84. 2009
  4. ncbi Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN
    A Custodio
    Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 12:310-4. 2010
  5. ncbi Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer
    J A Garcia-Saenz
    Service de Oncología Médica, Hospital Clinico San Carlos, Madrid, Spain
    J Chemother 20:632-9. 2008

Collaborators

  • Eduardo Diaz-Rubio
  • M Martin
  • Javier Puente
  • Ana Belén Custodio Carretero
  • J A Garcia-Saenz
  • A Casado
  • Laura Rodríguez Lajusticia
  • Antonio Calles Blanco
  • Jose Luis Gonzalez Larriba
  • L Rodriguez
  • A Calles
  • Beatriz García Paredes
  • Eduardo Díaz-Rubio García
  • C Bueno
  • Jose Angel Garcia Saenz
  • J Bobokova
  • Florentino Hernando Trancho
  • Jana Bobokova

Detail Information

Publications5

  1. ncbi Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review
    Ana Belén Custodio Carretero
    Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 10:560-71. 2008
    ....
  2. ncbi Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer
    Ana Belén Custodio
    Medical Oncology Department, Hospital Universitario Clinico San Carlos, Center affiliate to the Red Temática de Investigación Cooperativa RD06 0020 0021, Instituto de Salud Carlos III ISCIII, Madrid, Spain
    J Thorac Oncol 4:891-910. 2009
    ..Additional studies will be required to determine whether these markers are useful in selecting patients for adjuvant platinum-based chemotherapy...
  3. ncbi Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions
    Ana Custodio
    Department of Medical Oncology, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Cancer Treat Rev 35:676-84. 2009
    ..The main goal of this paper is reviewing this topic...
  4. ncbi Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN
    A Custodio
    Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 12:310-4. 2010
    ..A review of the pertinent literature supporting the future use of therapies against epidermal growth factor receptor (EGFR) in highgrade gliomas is also provided...
  5. ncbi Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer
    J A Garcia-Saenz
    Service de Oncología Médica, Hospital Clinico San Carlos, Madrid, Spain
    J Chemother 20:632-9. 2008
    ..0% in Ki-67 > or =20% tumors, P = 0.015). Adverse effects were mild. The combination of bevacizumab and a metronomic-based chemotherapy was effective, well tolerated and provided clinical benefit in heavilytreated MBC patients...